The assessment of glycemic variability and its impact on diabetes-related complications: An overview

Diabetes Technology and Therapeutics

Volumn 11, Issue 10, 2009, Pages 623-633

  Weber, Christian ^a   Schnell, Oliver ^b  

^a Institute for Medical Informatics and Biostatistics   (Switzerland)

^b INSTITUT FÜR DIABETESFORSCHUNG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C;

BLOOD GLUCOSE MONITORING; CARDIOVASCULAR RISK; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; GLYCEMIC INDEX; HYPERGLYCEMIA; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC RETINOPATHY; GLYCEMIC INDEX;

EID: 70350751568     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2009.0043     Document Type: Review

References (99)

1. Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-yr cardiovascular mortality men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-444.
2. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H: Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall study. Br Med J (Clin Res Ed) 1983;287:867-870.
3. The effect of intensive treatment of diabetes on the development and progression of long-term complications insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-986.
4. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B; Diabetes Control and Complications Trial=Epidemiology of Diabetes Interventions and Complications (DCCT=EDIC) Study Research Group: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353:2643-2653.
5. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-853. Erratum in: Lancet 1999;354:602.
6. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412.
7. Effect of intensive blood-glucose control with metformin complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854-865. Erratum in: Lancet 1998; 352:1558.
8. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS. UK Prospective Diabetes Study Group. BMJ 1998;317: 703-713.
9. Adler AI, Stevens RJ, Neil A, Stratton IM, Boulten AJM, Holman RR: UKPDS 59: Hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care 2002;25:894-899.
10. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589.
11. Gaede P, Lund-Andersen H, Parving HH, Pedersen O: Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-591.
12. Singer DE, Coley CM, Samet JH, Nathan DM: Tests of glycemia in diabetes mellitus. Their use in establishing a diagnosis and in treatment. Ann Intern Med 1989;110:125-137.
13. Nathan DM, Singer DE, Hurxthal K, Goodson JD: The clinical information value of the glycosylated hemoglobin assay. N Engl J Med 1984;310:341-346.
14. Tahara Y, Shima K: Kinetics of HbA1c, glycated albumin, and fructosamine and analysis of their weight functions against preceding plasma glucose level. Diabetes Care 1995; 18:440-447.
15. Ceriello A: The emerging role of post-prandial hyperglycaemic spikes in the pathogenesis of diabetic complications. Diabet Med 1998;15:188-193.
16. Ceriello A: The possible role of postprandial hyperglycaemia in the pathogenesis of diabetic complications. Diabetologia 2003;46(Suppl 1):M9-M16.
17. Gallagher A, Home PD: The effect of improved postprandial blood glucose control on post-prandial metabolism and markers of vascular risk in people with type 2 diabetes. Diabetes Res Clin Pract 2005;67:196-203.
18. Hanefeld M, Koehler C, Henkel E, Fuecker K, Schaper F, Temelkova-Kurktschiev T: Post-challenge hyperglycaemia relates more strongly than fasting hyperglycaemia with carotid intima-media thickness: the RIAD Study. Risk Factors in Impaired Glucose Tolerance for Atherosclerosis and Diabetes. Diabet Med 2000;17:835-840.
19. Bonora E: Postprandial peaks as a risk factor for cardiovascular disease: epidemiological perspectives. Int J Clin Pract Suppl 2002;(129):5-11.
20. Temelkova-Kurktschiev TS, Koehler C, Henkel E, Leonhardt W, Fuecker K, Hanefeld M: Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care 2000;23:1830-1834.
21. Derr R, Garrett E, Stacy GA, Saudek CD: Is HbA1c affected by glycemic instability? Diabetes Care 2003;26:2728-2733.
22. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C: Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006;295:1681-1687.
23. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-821.
24. Brownlee M: The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005;54:1615-1625.
25. Ceriello A, Esposito K, Piconi L, Ihnat MA, Thorpe JE, Testa R, Boemi M, Giugliano D: Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 2008;57:1349-1354.
26. Siegelaar SE, Kulik W, van Lenthe H, Mukherjee R, Hoekstra JB, Devries JH: A randomized clinical trial comparing the effect of basal insulin and inhaled mealtime insulin on glucose variability and oxidative stress. Diabetes Obes Metab 2009;11:709-714.
27. De Fronzo RA, Hendler R, Christensen N: Stimulation of counterregulatory hormonal responses in diabetic man by a fall in glucose concentration. Diabetes 1980;29:125-131.
28. Libby P, Maroko PR, Braunwald E: The effect of hypoglycemia on myocardial ischemic injury during acute experimental coronary artery occlusion. Circulation 1975;51:621-626.
29. Desouza C, Salazar H, Cheong B, Murgo J, Fonseca V: Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care 2003;26: 1485-1489.
30. Svensson AM, McGuire DK, Abrahamsson P, Dellborg M: Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events. Eur Heart J 2005;26:1255-1261.
31. Brownlee M, Hirsch IB: Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. JAMA 2006;295:1707-1708.
32. Hirsch IB, Brownlee M: The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 2007;30:186-187.
33. Gerich JE, Odawara M, Terauchi Y: The rationale for paired pre- and postprandial self-monitoring of blood glucose: the role of glycemic variability in micro- and macrovascular risk. Curr Med Res Opin 2007;23:1791-1798.
34. Guerci B: [Asymptomatic glycemic instability: how to measure it and which clinical applications?]. Diabetes Metab 2003;29:179-188.
35. Schlichtkrull J, Munck O, Jersild M: The M-value, an index of blood sugar control in diabetics. Acta Med Scand 1965;177: 95-102.
36. Mirouze J, Sathinger A, Sany C, Jaffiol C: [Insulin efficiency coefficient. M coefficient of Schlichtkrull corrected and simplified by the continuous blood glucose recording technique.]. Diabete 1963;11:267-273.
37. Hirsch IB, Brownlee M: Should minimal blood glucose variability become the gold standard of glycemic control? J Diabetes Complications 2005;19:178-181.
38. Wojcicki JM: "J"-index. A new proposition of the assessment of current glucose control in diabetic patients. Horm Metab Res 1995;27:41-42.
39. Vogelzang M, van der Horst IC, Nijsten MW: Hyperglycaemic index as a tool to assess glucose control: a retrospective study. Crit Care 2004;8:R122-R127.
40. Kovatchev BP, Clarke WL, Breton M, Brayman K, McCall A: Quantifying temporal glucose variability in diabetes via continuous glucose monitoring: mathematical methods and clinical application. Diabetes Technol Ther 2005;7:849-862.
41. Kovatchev BP, Cox DJ, Kumar A, Gonder-Frederick L, Clarke WL: Algorithmic evaluation of metabolic control and risk of severe hypoglycemia in type 1 and type 2 diabetes using self-monitoring blood glucose data. Diabetes Technol Ther 2003;5:817-828.
42. Molnar GD, Taylor WF, Ho MM: Day-to-day variation of continuously monitored glycaemia: a further measure of diabetic instability. Diabetologia 1972;8:342-348.
43. Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF: Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 1970; 19:644-655.
44. Ryan EA, Shandro T, Green K, Paty BW, Senior PA, Bigam D, Shapiro AM, Vantyghem MC: Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. Diabetes 2004;53: 955-962.
45. Hill NR, Hindmarsh PC, Stevens RJ, Stratton IM, Levy JC, Matthews DR: A method for assessing quality of control from glucose profiles. Diabet Med 2007;24:753-758.
46. McDonnell CM, Donath SM, Vidmar SI, Werther GA, Cameron FJ: A novel approach to continuous glucose analysis utilizing glycemic variation. Diabetes Technol Ther 2005;7:253-263.
47. Kovatchev BP, Otto E, Cox D, Gonder-Frederick L, Clarke W: Evaluation of a new measure of blood glucose variability in diabetes. Diabetes Care 2006;29:2433-2438.
48. Kovatchev BP, Cox DJ, Gonder-Frederick LA, Clarke W: Symmetrization of the blood glucose measurement scale and its applications. Diabetes Care 1997;20:1655-1658.
49. Krinsley JS: Glycemic variability: a strong independent predictor of mortality in critically ill patients. Crit Care Med 2008;36:3008-3013.
50. Egi M, Bellomo R, Stachowski E, French CJ, Hart G: Variability of blood glucose concentration and short-term mortality in critically ill patients. Anesthesiology 2006;105: 244-252.
51. Wintergerst KA, Buckingham B, Gandrud L, Wong BJ, Kache S, Wilson DM: Association of hypoglycemia, hyperglycemia, and glucose variability with morbidity and death in the pediatric intensive care unit. Pediatrics 2006;118: 173-179.
52. Dossett LA, Cao H, Mowery NT, Dortch MJ, Morris JM, May AK: Blood glucose variability is associated with mortality in the surgical intensive care unit. Am Surg 2008;74:679-685.
53. Buckingham B, Caswell K, Wilson DM: Real-time continuous glucose monitoring. Curr Opin Endocrinol Diabetes Obes 2007;14:288-295.
54. Melki V, Ayon F, Fernandez M, Hanaire-Broutin H: Value and limitations of the Continuous Glucose Monitoring System in the management of type 1 diabetes. Diabetes Metab 2006;32:123-129.
55. Monnier L, Colette C, Boegner C, Pham TC, Lapinski H, Boniface H: Continuous glucose monitoring in patients with type 2 diabetes: why? when? whom? Diabetes Metab 2007; 33:247-252.
56. Newman S, Cooke D, Casbard A, Walker S, Meredith S, Nunn A, Steed L, Manca A, Sculpher M, Barnard M, Kerr D, Weaver J, Ahlquist J, Hurel S: A randomised controlled trial to compare minimally invasive glucose monitoring devices with conventional monitoring in the management of insulintreated diabetes mellitus (MITRE). Health Technol Assess 2009;13(28):1.
57. Monnier L, Colette C, Dunseath GJ, Owens DR: The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 2007; 30:263-269.
58. Landgraf R: The relationship of postprandial glucose to HbA1c. Diabetes Metab Res Rev 2004;20(Suppl 2):S9-S12.
59. Leiter LA, Ceriello A, Davidson JA, Hanefeld M, Monnier L, Owens DR, Tajima N, Tuomilehto J: Postprandial glucose regulation: new data and new implications. Clin Ther 2005; 27(Suppl B):S42-S56.
60. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, Ziegelasch HJ, Lindner J: Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996;39:1577-1583.
61. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M: Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM Trial. JAMA 2003;290:486-494.
62. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M: Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004;25:10-16.
63. Coutinho M, Gerstein HC, Wang Y, Yusuf S: The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years1. Diabetes Care 1999;22:233-240.
64. Smith NL, Barzilay JI, Shaffer D, Savage PJ, Heckbert SR, Kuller LH, Kronmal RA, Resnick HE, Psaty BM: Fasting and 2-hour postchallenge serum glucose measures and risk of incident cardiovascular events in the elderly: the Cardiovascular Health Study. Arch Intern Med 2002;162:209-216.
65. Vaccaro O, Ruth KJ, Stamler J: Relationship of postload plasma glucose to mortality with 19-yr follow-up. Comparison of one versus two plasma glucose measurements in the Chicago Peoples Gas Company Study. Diabetes Care 1992; 15:1328-1334.
66. Lowe LP, Liu K, Greenland P, Metzger BE, Dyer AR, Stamler J: Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men. The Chicago Heart Association Detection Project in Industry Study. Diabetes Care 1997;20:163-169.
67. Orencia AJ, Daviglus ML, Dyer AR, Walsh M, Greenland P, Stamler J: One-hour postload plasma glucose and risks of fatal coronary heart disease and stroke among nondiabetic men and women: the Chicago Heart Association Detection Project in Industry (CHA) Study. J Clin Epidemiol 1997;50: 1369-1376.
68. Nakagami T: Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia 2004;47:385-394.
69. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet 1999;354:617-621.
70. Meigs JB, Nathan DM, D'Agostino RB, Wilson PW: Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care 2002;25: 1845-1850.
71. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A: Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999;22: 920-924.
72. Rodriguez BL, Lau N, Burchfiel CM, Abbott RD, Sharp DS, Yano K, Curb JD: Glucose intolerance and 23-year risk of coronary heart disease and total mortality: the Honolulu Heart Program. Diabetes Care 1999;22:1262-1265.
73. De Vegt F, Dekker JM, Ruhe HG, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ: Hyperglycaemia is associated with allcause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 1999;42:926-931.
74. Shaw JE, Hodge AM, de Court, Chitson P, Zimmet PZ: Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality. Diabetologia 1999;42:1050-1054.
75. Balkau B, Shipley M, Jarrett RJ, Pyorala K, Pyorala M, Forhan A, Eschwege E: High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 1998;21:360-367.
76. Qiao Q, Pyorala K, Pyorala M, Nissinen A, Lindstrom J, Tilvis R, Tuomilehto J: Two-hour glucose is a better risk predictor for incident coronary heart disease and cardiovascular mortality than fasting glucose. Eur Heart J 2002; 23:1267-1275.
77. Barrett-Connor E, Ferrara A: Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo Study. Diabetes Care 1998;21:1236-1239.
78. Cavalot F, Petrelli A, Traversa M, Bonomo K, Fiora E, Conti M, Anfossi G, Costa G, Trovati M: Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab 2006;91:813-819.
79. Saydah SH, Miret M, Sung J, Varas C, Gause D, Brancati FL: Postchallenge hyperglycemia and mortality in a national sample of U.S. adults. Diabetes Care 2001;24:1397-1402.
80. Brunner EJ, Shipley M, Witte DR, Fuller JH, Marmot MG: Relation between blood glucose and coronary mortality over 33 years in the Whitehall study. Diabetes Care 2006;29: 26-31.
81. Haheim LL, Holme I, Hjermann I, Leren P: Nonfasting serum glucose and the risk of fatal stroke in diabetic and nondiabetic subjects. 18-year follow-up of the Oslo Study. Stroke 1995;26:774-777.
82. Wannamethee SG, Perry IJ, Shaper AG: Nonfasting serum glucose and insulin concentrations and the risk of stroke. Stroke 1999;30:1780-1786.
83. Oizumi T, Daimon M, Jimbu Y, Wada K, Kameda W, Susa S, Yamaguchi H, Ohnuma H, Tominaga M, Kato T: Impaired glucose tolerance is a risk factor for stroke in a Japanese sample-the Funagata study. Metabolism 2008;57:333-338.
84. Medina RA, Pugh JA, Monterrosa A, Cornell J: Minority advantage in diabetic end-stage renal disease survival on hemodialysis: due to different proportions of diabetic type? Am J Kidney Dis 1996;28:226-234.
85. Morioka T, Emoto M, Tabata T, Shoji T, Tahara H, Kishimoto H, Ishimura E, Nishizawa Y: Glycemic control is a predictor of survival for diabetic patients on hemodialysis. Diabetes Care 2001;24:909-913.
86. Oomichi T, Emoto M, Tabata T, Morioka T, Tsujimoto Y, Tahara H, Shoji T, Nishizawa Y: Impact of glycemic control on survival of diabetic patients on chronic regular hemodialysis: a 7-year observational study. Diabetes Care 2006; 29:1496-1500.
87. Wu MS, Yu CC, Yang CW, Wu CH, Haung JY, Hong JJ, Fan Chiang CY, Huang CC, Leu ML: Poor pre-dialysis glycaemic control is a predictor of mortality in type II diabetic patients on maintenance haemodialysis. Nephrol Dial Transplant 1997;12:2105-2110.
88. Kilpatrick ES, Rigby AS, Atkin SL: The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 2006;29:1486-1490.
89. Service FJ, O'Brien PC: The relation of glycaemia to the risk of development and progression of retinopathy in the Diabetic Control and Complications Trial. Diabetologia 2001; 44:1215-1220.
90. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28:103-117.
91. Shiraiwa T, Kaneto H, Miyatsuka T, Kato K, Yamamoto K, Kawashima A, Kanda T, Suzuki M, Imano E, Matsuhisa M, Hori M, Yamasaki Y: Postprandial hyperglycemia is a better predictor of the progression of diabetic retinopathy than HbA1c in Japanese type 2 diabetic patients. Diabetes Care 2005;28:2806-2807.
92. Chaturvedi N, Stevens LK, Fuller JH, Lee ET, Lu M: Risk factors, ethnic differences and mortality associated with lower-extremity gangrene and amputation in diabetes. The WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001;44(Suppl 2):S65-S71.
93. Woerle HJ, Pimenta WP, Meyer C, Gosmanov NR, Szoke E, Szombathy T, Mitrakou A, Gerich JE: Diagnostic and therapeutic implications of relationships between fasting, 2-hour postchallenge plasma glucose and hemoglobin a1c values. Arch Intern Med 2004;164:1627-1632.
94. Raz I, Wilson PW, Strojek K, Kowalska I, Bozikov V, Gitt AK, Jermendy G, Campaigne BN, Kerr L, Milicevic Z, Jacober SJ: Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 2009;32:381-386.
95. The Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail- Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559.
96. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD: Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360: 129-139.
97. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, De Galan BE, Joshi R, Travert F: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572.
98. Gill GV, Woodward A, Casson IF, Weston PJ: Cardiac arrhythmia and nocturnal hypoglycaemia in type 1 diabetes- the 'dead in bed' syndrome revisited. Diabetologia 2009; 52:42-45.
99. Wolever TM, Chiasson JL, Csima A, Hunt JA, Palmason C, Ross SA, Ryan EA: Variation of postprandial plasma glucose, palatability, and symptoms associated with a standardized mixed test meal versus 75 g oral glucose. Diabetes Care 1998; 21:336-340.